selectshandong@shandong.cn
中 日 한 EN DE FR
SELECTSHANDONG

Yantai in Shandong Province Prioritizes the Cultivation and Development of the Biomedical Industry

Source：Haibao News 02-26-2025 09:00:00

Recently, the Market Supervision Work Conference of Yantai, Shandong was convened for review and exchange of insights on the work in 2024 and to outline the city's market supervision objectives for 2025. At the conference, biomedicine was identified as a strategic emerging industry that Yantai aims to cultivate and develop. As the principal governing body of the biomedical industrial chain, Yantai's market supervision departments have been intensifying the implementation of the chain owner system, thereby accelerating the revitalization of the pharmaceutical sector in Shandong.

Additionally, Yantai has established 10 new biomedical innovation platforms at or above the provincial level, initiated the construction of Shandong's first testing laboratory for radiopharmaceuticals, and formalized an agreement to establish Academician Wu Yuzhang's Workstation. Boan Biotech has been recognized as a specialized and innovative "little giant" enterprise; Yantai Hongyuan Oxygen Industry has been designated as a national single champion in the manufacturing sector; Luye Pharma Group's Class 5.1 imported branded drug, Lurbinectedin, has entered the domestic market; and CSPC Baike's Class I new drug, Jinlitai, is produced in Yantai. Currently, 31 Class I new drugs and 12 Class III medical devices are in stages of clinical trials or marketing application, marking the onset of a surge in innovative achievements.